ADAR1 Capital Management »

Design Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Design Therapeutics (DSGN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Design Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Design Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Design Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $29k 7.2k 4.03
2023-12-31 $5.3k 2.0k 2.65

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Design Therapeutics

Sr One Capital Management
Logos Global Management
BlackRock
Frazier Life Sciences Management
Baker Bros. Advisors
Point72 Asset Management
Tang Capital Management
Vanguard Group
Almitas Capital
FMR
Geode Capital Management
State Street Corporation
Acadian Asset Management
D. E. Shaw & Co
Citadel Advisors

View all funds holding Design Therapeutics